These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 34741677)

  • 1. Highlights in clinical medicine-Giant cell arteritis, polymyalgia rheumatica and Takayasu's arteritis: pathogenic links and therapeutic implications.
    Solimando AG; Vacca A; Dammacco F
    Clin Exp Med; 2022 Nov; 22(4):509-518. PubMed ID: 34741677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunopathogenesis, diagnosis, and treatment of giant cell arteritis, temporal arteritis, polymyalgia rheumatica, and Takayasu's arteritis.
    Hellmann DB
    Curr Opin Rheumatol; 1993 Jan; 5(1):25-32. PubMed ID: 8094625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice.
    Lally L; Spiera R
    Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):803-812. PubMed ID: 31427056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giant Cell Arteritis and Polymyalgia Rheumatica: Treatment Approaches and New Targets.
    Nepal D; Putman M; Unizony S
    Rheum Dis Clin North Am; 2023 Aug; 49(3):505-521. PubMed ID: 37331730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
    Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of polymyalgia rheumatica and giant cell arteritis.
    Salvarani C; Pipitone N; Versari A; Hunder GG
    Nat Rev Rheumatol; 2012 Sep; 8(9):509-21. PubMed ID: 22825731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclinical giant cell arteritis in polymyalgia rheumatica: Concurrent conditions or a common spectrum of inflammatory diseases?
    Salvarani C; Padoan R; Iorio L; Tomelleri A; Terrier B; Muratore F; Dasgupta B
    Autoimmun Rev; 2024 Jan; 23(1):103415. PubMed ID: 37625672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica.
    El Chami S; Springer JM
    Rheum Dis Clin North Am; 2022 May; 48(2):493-506. PubMed ID: 35400374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Care Vasculitis: Polymyalgia Rheumatica and Giant Cell Arteritis.
    Pioro MH
    Prim Care; 2018 Jun; 45(2):305-323. PubMed ID: 29759126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
    Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
    JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica.
    Braun N; Fritz P; Rieth A; Schroth W; Kimmel M; Biegger D; Zakim D; Alscher MD
    J Rheumatol; 2009 Oct; 36(10):2269-76. PubMed ID: 19684157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis.
    Matteson EL; Buttgereit F; Dejaco C; Dasgupta B
    Rheum Dis Clin North Am; 2016 Feb; 42(1):75-90, viii. PubMed ID: 26611552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.
    Camellino D; Matteson EL; Buttgereit F; Dejaco C
    Nat Rev Rheumatol; 2020 Sep; 16(9):481-495. PubMed ID: 32759996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Giant cell arteritis and polymyalgia rheumatica.
    Hunder GG
    Med Clin North Am; 1997 Jan; 81(1):195-219. PubMed ID: 9012761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polymyalgia rheumatica and Giant Cell Arteritis - Update on Diagnosis and Therapy].
    Becker M
    Praxis (Bern 1994); 2020; 109(5):347-354. PubMed ID: 32233763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis.
    Nageswaran P; Ahmed S; Tahir H
    Expert Opin Emerg Drugs; 2024 Mar; 29(1):5-17. PubMed ID: 38180809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymyalgia rheumatica and giant cell arteritis.
    Partain K; Bradley J; Brandt KD
    Indiana Med; 1988 Jan; 81(1):11-6. PubMed ID: 3278053
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis.
    Emamifar A; Ellingsen T; Hermann AP; Hess S; Gerke O; Ahangarani Farahani Z; Syrak Hansen P; Jensen Hansen IM; Thye-Rønn P
    Sci Rep; 2021 Mar; 11(1):6220. PubMed ID: 33737697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Giant cell arteritis and polymyalgia rheumatica: an update.
    González-Gay MA; Pina T
    Curr Rheumatol Rep; 2015 Feb; 17(2):6. PubMed ID: 25618572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica.
    De Miguel E; Karalilova R; Macchioni P; Ponte C; Conticini E; Cowley S; Tomelleri A; Monti S; Monjo I; Batalov Z; Klinowski G; Falsetti P; Kane DJ; Campochiaro C; Hočevar A
    Ann Rheum Dis; 2024 Feb; 83(3):335-341. PubMed ID: 37932008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.